India’s pharma and healthcare startups raised $69.8 million across 18 funding rounds in July 2026, marking a sharp slowdown from previous months amid a shift towards later-stage investments and increased focus on established businesses, according to Tracxn data.
India’s pharma and healthcare startups raised $69.8 million across 18 funding rounds in July 2026, according to Tracxn data cited by Express Pharma. The figure marked a sharp slowdown from June and was also well below the same month a year earlier, highlighting a softer stretch for capital deployment in the sector even as investor interest remained active at the later stages.
Tracxn’s data shows that late-stage deals made up just over half of July’s total, at 53.4%, while early-stage investment accounted for 34.4% and seed funding for 12.3%. That mix suggests money continued to flow towards more established businesses rather than very early ventures, even as overall monthly funding fell. The July total also followed a volatile year for the sector, after monthly funding swung from $57.9 million in August 2025 to $291.5 million in April 2026 before easing to $106.5 million in June and then $69.8 million in July.
The biggest transaction in July was a $37 million round for Iswarya Fertility Center. Other notable deals included Arp at $10 million, Age Care Labs at $9 million and Supply6 at $5 million, while V6 Clinics raised $2 million, Mandrake Bio $1.9 million and FibroHeal $1.5 million. Unilever Ventures, Antler and Unicorn India Ventures were among the most active venture capital firms in the period, backing Supply6, Mandrake Bio and Bioscan Research respectively.
The July funding snapshot came against a broader backdrop of robust dealmaking in Indian pharma and healthcare. Grant Thornton Bharat’s Pharma and Healthcare Dealtracker, as reported by Pharmabiz and The Times of India, said the sector recorded 65 transactions worth about $13.9 billion in the second quarter of 2026, with overall value underpinned by Sun Pharmaceutical Industries’ $11.8 billion acquisition of Organon & Co. The reports also said outbound transactions accounted for 96% of deal value and that Commerce Minister Piyush Goyal had recently met industry representatives to discuss higher spending on research, clinical work and advanced therapies.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
